Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Adult
Aged
Aged, 80 and over
Clinical Decision-Making
/ methods
Clinical Trials as Topic
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Models, Biological
Myelodysplastic Syndromes
/ mortality
Patient Selection
Predictive Value of Tests
Prognosis
ROC Curve
Reference Values
Research Design
Retrospective Studies
Risk Assessment
/ methods
Risk Factors
Young Adult
IPSS
IPSS-R
Myelodysplastic syndromes
international prognostic scoring system
revised international prognostic scoring system
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
1
12
2018
medline:
21
7
2020
entrez:
1
12
2018
Statut:
ppublish
Résumé
In clinical practice, patients with myelodysplastic syndromes (MDS) are usually classified in low or high-risk groups to take therapeutic decisions, conservative for low-risk, whereas active for high-risk. Nevertheless, in the Revised International Prognostic Scoring System (IPSS-R) is not well stated which patients are low or high-risk. This study was aimed to ascertain in 364 MDS patients which IPSS-R threshold better dichotomized in low vs. high-risk. The best dichotomization was obtained with an IPSS-R cut-point of 3. Accordingly, 68% patients were classified as low-risk (median OS, 61.3 months) and 32% as high-risk MDS (median OS, 13.9 months) (
Identifiants
pubmed: 30499738
doi: 10.1080/10428194.2018.1542151
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM